The fact
Science Corporation, a brain-computer interface (BCI) startup founded by Max Hodak, cofounder of Neuralink, has secured regulatory approval from Europe's medical device authority to commercialize a retinal implant that restores vision lost to advanced age-related macular degeneration. The device, called PRIMA, consists of a chip placed under the retina paired with camera-equipped glasses that allow patients to read letters, numbers, and words again.
Context
Age-related macular degeneration (AMD) is the leading cause of vision loss in people over 60 in developed countries, affecting roughly 200 million people worldwide. Until now, no treatment effectively restored lost central vision, only therapies that slowed disease progression. PRIMA functions as a retinal prosthesis: the camera on the glasses captures the image, processes it, and wirelessly transmits it to the chip under the retina, which stimulates remaining bipolar cells. This is the first time a BCI has received regulatory approval to restore vision.
Analysis
This approval represents a milestone not just for Science Corporation but for the entire neurotechnology field. While companies like Neuralink and Synchron focus on thought-controlled device interfaces, Science Corporation addressed a more immediate problem with enormous market potential: age-related vision loss. The fact that Hodak left Neuralink and built a company that reached market before it reveals fundamentally different strategies. Neuralink is pursuing a general-purpose neural platform, technically more ambitious and regulatorily more complex. Science Corporation went straight for a surgical application with a clear clinical endpoint: reading again. From a business perspective, the AMD market is massive, and PRIMA could become the standard of care if long-term results hold up. The EU approval also sets a regulatory precedent that could accelerate similar approvals for other BCIs.
What to watch
The next milestone is FDA approval in the United States, which could take 12 to 24 months. Implant durability will also be critical, as the chip must function for years without degradation. Procedure cost and insurance coverage will determine the treatment's real-world reach. Finally, Science Corporation's success could pave the way for other BCI approvals in Europe, accelerating the entire neurotechnology sector.
Sources: Yahoo Finance, AndroGuider, NewsBytes
